Why Managing Jardiance Side Effects Is Critical for Clinicians

Clinical Vignette

Clinicians must treat empagliflozin safety surveillance as a routine part of prescribing. Safety communications and real‑world analyses identify signals in empagliflozin’s safety profile (real-world safety profile of empagliflozin).

Prompt recognition and management of adverse events (e.g., DKA, severe infections, volume depletion) reduce avoidable harm and care escalation. Early action also helps preserve patient trust.

Although many SGLT2 adverse effects are mild, some require immediate intervention. The FDA label highlights volume depletion and diabetic ketoacidosis as serious risks requiring intervention (Jardiance FDA prescribing information (2023)).

Rare cases of necrotizing fasciitis (Fournier’s gangrene) have been reported with SGLT2 inhibitors per FDA safety communications, reinforcing the need for vigilance (2023–2024 FDA MedWatch alerts). Genital mycotic infections are a common reason for discontinuation; UTI‑related discontinuation varies across studies and comparators (real-world safety profile of empagliflozin).

This article provides a concise best-practices checklist for point-of-care monitoring, documentation, and patient counseling.

Order and document the following baseline tests.

Use clinical judgment to select relevant labs and imaging for each patient and to guide ongoing monitoring.

Rounds AI’s evidence-linked answers can help you verify these risks quickly at the bedside. Clinicians using Rounds AI gain rapid, citable guidance to support safer prescribing decisions — learn more about Rounds AI’s approach to medication safety and team implementation.

Best Practice 1: Conduct Baseline Renal and Hepatic Assessment

Baseline renal and hepatic assessment is essential before initiating empagliflozin (Jardiance). The FDA prescribing information sets an eGFR threshold for initiation and guidance that clinicians must review (FDA label). Major kidney guidelines also emphasize baseline kidney function when starting SGLT2 inhibitors (KDIGO 2024; NICE NG203). Confirming renal and hepatic status balances safety with the demonstrable kidney benefit seen in EMPA‑KIDNEY, where empagliflozin reduced the risk of kidney disease progression or cardiovascular death by about 28% (hazard ratio ≈ 0.72) versus placebo (EMPA‑KIDNEY). Rounds AI surfaces primary‑source citations like these instantly so you can verify the trial language at the point of care.

Order and document the following baseline tests before prescribing:

• serum creatinine with calculated eGFR to establish current kidney function
• liver function tests: ALT, AST, and bilirubin to assess hepatic impairment

Order tests that reflect recent status and record results in the chart. Note the eGFR value used for the prescribing decision and cite the FDA label or guideline supporting your choice. Clear documentation helps team members and supports safe follow-up.

Be alert for common pitfalls. Old labs may not reflect recent acute kidney injury. Recent AKI, volume depletion, or nephrotoxic exposures require repeat testing and reassessment. Different guidance sources vary on the lower eGFR limit for use; reconcile local formulary rules with national guidance and the FDA label. When uncertainty remains, document the rationale and plan for monitoring.

Clinicians using Rounds AI can quickly reference the guideline and label language that underpins these thresholds at the point of care. Rounds AI’s evidence‑linked answers help you capture the citation trail you relied on when documenting a prescribing decision. Rounds AI can also display label‑specific dosing and indication nuances with citations. For hospital leaders evaluating workflow tools, learn more about how Rounds AI supports guideline‑aligned, verifiable prescribing decisions. Rounds AI offers HIPAA‑aware architecture with an optional BAA, SSO integration, and priority support for health systems.

A 68-year-old patient has type 2 diabetes and an outpatient eGFR of 45 mL/min/1.73 m². The FDA label notes that initiation is not recommended below specific eGFR thresholds and provides dosing guidance near this range (FDA label). No dose adjustment is required based on eGFR; for glycemic control, initiation is not recommended below eGFR 30 mL/min/1.73 m² because of reduced glucose‑lowering efficacy, while for heart‑failure or CKD indications use may be appropriate at lower eGFR values per the label and guideline recommendations. Some regulatory product information and national documents discuss continued use or indication‑specific considerations at lower eGFR values in select circumstances (AusPAR product information). In practice, document the exact eGFR used, reference the label or guideline you followed, and record a monitoring plan. This ensures transparency and supports safe follow‑up if renal function changes.

Best Practice 2: Educate Patients on Genital and Urinary Tract Infection Risk

Genital mycotic infections occur in up to 10% of patients taking empagliflozin, while urinary tract infections occur in up to 8% in pooled trial data (Clinical Recommendations for Managing Genitourinary Infections). These events are usually mild to moderate. Prompt recognition and early treatment typically prevent escalation and avoid drug discontinuation, per the FDA prescribing information (Jardiance label, 2023). You may get the practical question: how to counsel patients on genital infections when using Jardiance? Use a brief, structured script at initiation and reinforce it at the first follow-up. A three-step counseling approach works well: educate on basic prevention and hydration, give a written handout with warning signs, and arrange early follow-up to reassess symptoms and tolerance (EMPR guidance; Drugs.com patient counseling). Written materials increase patient adherence to preventive hygiene measures and help patients know when to seek care. Keep the counseling script succinct and patient-centered. Use plain language, name the likely symptoms, and give clear actions for mild symptoms versus severe symptoms. For example:

"This medicine can raise the chance of yeast infections or urinary infections. Drink plenty of fluids, keep the groin area dry, and use breathable underwear. If you notice itching, unusual discharge, burning with urination, fever, or flank pain, contact the clinic right away. Most infections are easily treated if caught early."

Tie the script to Rounds AI's concise, citation-linked references clinicians can use to create accurate patient education and counseling points.

Document that you provided a handout and planned follow-up. Recommend a follow-up visit 2–4 weeks after starting empagliflozin to review symptoms and adherence; higher‑risk patients (for example, those with prior recurrent infections or immunosuppression) may warrant earlier contact. This schedule lets you catch early issues and reduce unnecessary discontinuation (EMPR guidance; Jardiance label, 2023). Teams using Rounds AI benefit from concise, citation-linked references when preparing patient education and handouts at the point of care. Rounds AI provides concise, citation‑linked references clinicians can use to create accurate patient education and counseling points. #

• Maintain adequate hydration as advised by your clinician; targets may differ for patients with heart failure or CKD (Clinical Recommendations for Managing Genitourinary Infections).

• Advise cotton underwear; avoid tight clothing (Managing SGLT2 Inhibitor‑Associated Genital Mycotic Infections).

• Schedule follow-up at 2–4 weeks to reassess symptoms and adherence (Managing SGLT2 Inhibitor‑Associated Genital Mycotic Infections).

Best Practice 3: Monitor for Volume Depletion and Electrolyte Imbalance

Empagliflozin can cause intravascular volume depletion and shifts in serum electrolytes. Symptoms range from mild dizziness to symptomatic hypotension, especially early after initiation. A minority of patients experienced symptomatic dehydration in early post‑initiation series (Mineral and Electrolyte Disorders With SGLT2i Therapy). Recognize this risk when starting or uptitrating therapy.

If you’re asking how to monitor dehydration and electrolyte changes in patients taking Jardiance, follow a short, targeted cadence. Assess and correct volume status before initiation and monitor renal function and vitals based on clinical judgment, especially in higher‑risk patients. Rounds AI can surface FDA label language and guideline excerpts to tailor monitoring by risk. Incorporate vital signs and orthostatic checks into early follow-up visits.

Identify patients at higher risk and increase monitoring intensity. Older adults, patients on loop diuretics, and those with low oral intake show higher rates of volume depletion in real‑world studies (Real‑world safety profile of empagliflozin (2024)). Consider more frequent labs and earlier phone or clinic checks for these groups.

Watch for electrolyte changes that require prompt attention. Monitor electrolytes based on comorbidities and concomitant diuretics/RAAS blockade; SGLT2 inhibitors are not typically associated with clinically significant hypokalemia. Escalate care when hypotension, rising creatinine, or marked electrolyte abnormalities appear.

Rounds AI can help synthesize guideline and label recommendations when you need to confirm a monitoring plan at the point of care. Clinicians using Rounds AI access concise, evidence‑linked summaries that make it easier to verify labs, timing, and high‑risk flags. Try Rounds AI’s 3‑day free trial to get evidence‑based answers with clickable citations on web and iOS. Learn more about Rounds AI’s approach to evidence‑based clinical answers if you want a citation‑first reference layer to support monitoring decisions.

Early vigilance matters. Jardiance (empagliflozin) offers meaningful benefits but carries predictable risks that require monitoring. The FDA prescribing information highlights the need for baseline renal assessment and ongoing renal function checks (Jardiance prescribing information, 2023). Real‑world safety analyses also note volume‑depletion signals and infection risks clinicians should watch for (Real‑world safety profile of empagliflozin, 2024).

Keep three practices front of mind this week:

1. Perform a baseline assessment, including renal function and volume status, before initiating therapy.
2. Provide targeted patient education plus a simple checklist covering hydration, signs of infection, and when to seek care.
3. Monitor for volume depletion and electrolyte changes with scheduled follow‑up and repeat labs as clinically indicated.

Rounds AI supports evidence‑linked decision making at the point of care by surfacing guideline and label citations clinicians can verify quickly. Clinicians using Rounds AI can streamline bedside verification when counseling patients or ordering baseline tests. Learn more about Rounds AI's approach to evidence‑linked clinical Q&A and point‑of‑care verification at https://joinrounds.com. A practical next step: add baseline labs to the prescription workflow and hand the checklist to patients at the time of prescribing.